Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab for Newly Diagnosed Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
- Status
- COMPLETED
- Phase
- PHASE2
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
- Status
- COMPLETED
- Phase
- PHASE3
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
- Status
- COMPLETED
- Phase
- PHASE3
Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
- Status
- COMPLETED
- Phase
- PHASE3
Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Doravirine, Rifapentine and Isoniazid Interaction
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Tolerability of Gefapixant (MK-7264) in Participants With Obstructive Sleep Apnea (MK-7264-039)
- Status
- COMPLETED
- Phase
- PHASE1
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
- Status
- WITHDRAWN
- Phase
- PHASE3
Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection
- Status
- COMPLETED
- Phase
- PHASE4
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2